FINWIRES · TerminalLIVE
FINWIRES

$BHC

8 stories mentioning BHCUpdated 11h ago

Every FINWIRES story that references BHC, newest first.

Wire

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 1.7%.The iShares Biotechnology ETF (IBB) was up 0.3%.In corporate news, Xencor (XNCR) shares rose nearly 11% after the company said it has reached a settlement agreement with AstraZeneca (AZN) subsidiary Alexion Pharma International to resolve a commercial dispute over US royalties on Ultomiris. AstraZeneca shares were down 1.2%.Eli Lilly (LLY) expanded its collaboration with Resilience to invest $750 million as part of its effort to boost US production of Lilly's KwikPen injectable device for diabetes and obesity medicines, Resilience said Thursday. Lilly shares were down 4.4%.Johnson & Johnson (JNJ) said it has entered into strategic agreements with Sail Biomedicines to advance the biotech's in vivo CAR-T therapy platform for immune-mediated diseases, including an equity investment and an exclusive option to buy Sail for $2.58 billion. Johnson & Johnson shares fell 3.8%.Bausch Health (BHC) shares surged 26% after it reported higher Q2 results and raised its 2026 revenue outlook.Regeneron Pharmaceuticals (REGN) shares were up 6.3% after it reported higher Q2 results.

$AZN$BHC$JNJ$LLY$REGN$XNCR
Wire

Update: Bausch Health Shares Rise After Higher Q2 Results, Raised 2026 Revenue Outlook

(Updates with the latest stock movement in the first paragraph and headline.)Bausch Health (BHC) shares were up roughly 27% in Thursday trading after the company reported higher Q2 results and raised its 2026 revenue outlook.The company reported Q2 adjusted earnings late Wednesday of $1.26 per diluted share, up from $0.90 a year earlier.Analysts polled by FactSet expected $0.99.Revenue for the quarter ended June 30 was $2.85 billion, compared with $2.53 billion a year earlier.Four analysts expected $2.61 billion.For 2026, the company now expects revenue of $10.79 billion to $11.04 billion, up from $10.67 billion to $10.92 billion previously. Four analysts expect $10.52 billion.Price: $5.98, Change: $+1.30, Percent Change: +27.78%

$BHC
Mining & Metals

Bausch Health Rises After Q2 Earnings, Revenue Beat Estimates

Bausch Health Companies (BHC.TO, BHC) rose 4.1% in after-hours trading after reporting adjusted second-quarter earnings of $1.26 per share, up from $0.90 a year earlier and above the FactSet consensus estimate of $0.99.Revenue rose to $2.85 billion from $2.53 billion in the year-ago quarter, topping the FactSet consensus estimate of $2.60 billion.The company also raised its full-year 2026 consolidated revenue guidance to a range of $10.79 billion to $11.04 billion.Bausch Health shares were last up $0.19 at $4.87 in US after-hours trading. The stock closed up C$0.16 at C$6.56 on the Toronto Stock Exchange.

$BHC$BHC.TO
Wire

Bausch Health Poised to Report Q2 Consolidated Revenue of $2.73 Billion, RBC Capital Markets Says

Bausch Health (BHC) is poised to report Q2 revenue of $2.73 billion and adjusted earnings before interest, taxes, depreciation, and amortization of $948 million, compared with the Street consensus of $2.67 billion and $978 million, RBC Capital Markets said in a Tuesday note.Key areas of focus for company's Q2 earnings include the Xifaxan patent litigation, management's view for monetizing the Bausch + Lomb (BLCO) asset to reduce RemainCo debt following the Xifaxan genericization, Solta Medical performance and margin normalization, among others, RBC said.RBC said that it expects forex continue to influence Bausch Health and Bausch + Lomb performance in Q2, albeit to different degrees and with tailwinds moderating relative to Q1.Bausch Health is scheduled to report its Q2 results on July 29.RBC maintained its sector perform rating on Bausch Health with a price target of $9.Price: $4.54, Change: $-0.15, Percent Change: -3.10%

$BHC$BLCO
Mining & Metals

Bausch Health, Solta Medical Say Thermage Brand Receives China Trademark Certification

Bausch Health Companies (BHC.TO, BHC) and Solta Medical after the close Thursday said that their Thermage brand received the AAA Well-Known Trademark Certification from the China Trademark Association, a designation awarded to 217 brands across mainland China recognizing brand reputation, consumer confidence and market influence."Joining an elite group of only 217 brands nationwide, this distinction cements Thermage's position as a leader in medical aesthetics and is a powerful validation of the reliability and confidence we have established with consumers and practitioners in China," said chief executive Thomas Appio. "It underscores our commitment to innovation with the highest standards of quality and safety."engineering consulting firm shares closed up $0.03 to $7.48 on Toronto Stock Exchange.

$BHC$BHC.TO
Mining & Metals

Bausch Health Q1 Adjusted Earnings, Revenue, Advance, Beating Estimates

Bausch Health (BHC.TO) up 3.6% in after-hours New York trade, after the company on Wednesday said its first-quarter adjusted earnings and revenue both rose, beating estimates.Adjusted net income, which excludes most one-time items, rose to US$296 million, or US$0.78 per share, from US$220 million, or US$0.59, in the prior-year period. Analysts polled by FactSet had expected US$0.67 per share.Consolidated revenue jumped 12% to US$2.52 billion, beating the US$2.4 billion FactSet forecast.Bausch Health maintained its fiscal 2026 revenue guidance of US$5.25 billion to US$5.4 billion and adjusted EBITDA of US$2.875 billion to US$2.95 billion, both excluding Bausch + Lomb."Our first quarter performance marks twelve consecutive periods of year-over-year growth in revenue, adjusted EBITDA for Bausch Health excluding Bausch + Lomb, reflecting strategic execution and disciplined accountability across our organization. We continue to invest in our pipeline, including the advancement of larsucosterol to treat alcohol-associated hepatitis, while pursuing business development opportunities aligned with our strategic priorities. With this momentum, we reaffirm our full-year 2026 outlook and remain focused on driving sustainable performance and shareholder value," said chief executive Thomas Appio.Bausch Health shares were last seen up US$0.20, to US$5.79 in after-hours trade. They closed down $0.11 to $7.66 on the Toronto Stock Exchange.

$BHC$BHC.TO
Mining & Metals

RBC Capital Trims Bausch Health Companies Price Target to US$9.00; Maintains Sector Perform

RBC Capital Market trimmed its price target on the shares of Bausch Health Companies (BHC.TO, BHC) by US$1.00 to US$9.00, with a sector-perform rating ahead of the company's first-quarter earnings.Analyst Douglas Miehm is forecasting revenue of US$2.43 billion, slightly above consensus forecast of US$2.41 billion.The lowered price target of US$9.00 reflects revised estimates and lowered total prescriptions for key drugs, Miehm says, noting that total prescriptions for Xifaxan 550mg formulation declined 6.2% y/y in the first quarter, following a 1.1% y/y decline in the fourth quarter. However, he anticipates volume losses will be partially offset by improved net pricing.Key areas of focus for the earnings include updates on the Xifaxan patent litigation, management's strategic vision for monetizing the Bausch & Lomb (BLCO.TO) asset, and the return to growth at Solta following a depressed fourth quarter, he adds.Bausch Health reports its first-quarter earnings after market close on April 29.Price: $7.81, Change: $+0.12, Percent Change: +1.56%

$BHC$BHC.TO
Wire

Bausch Health's Q1 Total Prescriptions Hurt by Exit From Federal Drug Pricing Programs, RBC Says

Bausch Health's (BHC) total prescriptions in Q1 were likely to be negatively impacted by the company's exit from the US federal drug pricing programs in October 2025, RBC Capital Markets said in a Monday note.Prescriptions of the 550-miiligram formulation of the company's top-selling Xifaxan, used to treat gastrointestinal conditions, dropped 6.2% in Q1 year over year after a 1.1% decline in Q4, RBC analysts said. They expect volume losses to be partially offset by improved net pricing and revised their Xifaxan revenue forecast to $480 million from $487 million.The company's Q1 revenue is projected at $2.43 billion, compared with the consensus of $2.41 billion, according to the note.Investors are likely to focus on the ongoing litigation involving Xifaxan's patent; Bausch Health's plan to monetize the Bausch + Lomb (BLCO) asset after the genericization of Xifaxan, expected in January 2028; and a growth rebound for its Solta Medical aesthetics business, the analysts said.Bausch Health is expected to report Q1 financial results after market-close on Wednesday.RBC maintained the company's stock rating at sector-perform and lowered the price target to $9 from $10.Price: $5.70, Change: $+0.07, Percent Change: +1.15%

$BHC$BLCO

Track with the FINWIRES app suite

FolioX
FolioX
Track BHC in your portfolio
WheelAI
WheelAI
Analyze BHC options with the wheel strategy
StockInsider
StockInsider
See market sentiment on BHC